Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px
Document › Details

Metabolon, Inc.. (12/20/10). "Press Release: Metabolon Identifies Adenosine-mediated Sickling in Sickle Cell Disease and Associated End Organ Damage". Research Triangle Park, NC.

Organisations Organisation Metabolon Inc.
  Group Metabolon (Group)
  Organisation 2 University of Texas, Health Science Center (Houston)
  Group University of Texas System
Product Product  metabolomics

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Novel Role of Adenosine Signaling in Sickle Cell Disease", in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.

Sickle cell disease (SCD), a devastating inherited blood disorder, is caused by a point mutation in the ß-globin chain of hemoglobin. Despite knowledge of the molecular defect associated with sickle hemoglobin (HbS), preventative approaches or mechanism-specific treatment options for the disease are lacking. Metabolon's biochemical profiling technology was used to understand the molecular events involved in the pathogenesis of red blood cell sickling, so that novel therapeutic strategies to treat this disease can be developed. Adenosine was discovered to be highly elevated in the blood of SCD transgenic mice. Lowering adenosine concentrations significantly reduced sickling, hemolysis and multiple organ damage in the mice. Thus, these findings demonstrate the power of Metabolon's global profiling technology to understand the underlying disease mechanism and to identify novel therapeutic possibilities to treat and prevent damage resulting from SCD.

Copies of the paper can be accessed at:

About Metabolon

Metabolon is a diagnostics and services company offering the industry's leading biochemical profiling platform. Metabolon's patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit or contact Matt Zaske at (919) 595-2200.

Record changed: 2016-03-19


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Metabolon (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px